Regeneron Downgrade Highlights at Least Some Risks

Health and Healthcare

Published: January 27, 2016 12:40 pm

Last Updated: January 13, 2020 2:30 pm

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) seems to have held up rather well against an analyst downgrade on Wednesday. Canaccord Genuity lowered its official rating to Hold from Buy. While the downgrade may not be positive, the firm’s John Newman slashed his Regeneron price target to $525 from $700 in his call.

The reasons that Canaccord Genuity targeted were moderating EYLEA growth, a slow Praluent start and competitive risks in 2016.

Praluent’s launch trajectory was targeted in this report as slower than expected. The blame is residual price concerns, followed by an injectable formulation and a typical flatter trajectory for lipid therapies. Newman further said that he was lowering U.S. peak sales estimates to $1.4 billion by 2025 from his prior peak view of $2.6 billion. He is also concerned that Amgen’s data outcomes will surface ahead of Regeneron’s and could give Amgen a temporary but slight advantage.

All in all, the belief here in the downgrade is that Regeneron’s pipeline should produce attractive, wholly owned growth drivers. The partnered assets are another matter, and the report signals that the upside numbers from partnered assets are priced into the stock.

ALSO READ: 7 Great Consumer-Driven Companies That Need to Start Paying Dividends in 2016

Newman’s report said:

We anticipate a slowing growth trajectory for EYLEA, as we believe the boost from Protocol-T has largely been realized. Specifically, we model ~22.5% annual US growth in 2016, ~15% in 2017, 12.5% in 2018, and 10% in 2019. Importantly, we believe the greater adoption of pharmacotherapy in DME versus laser will benefit EYLEA, but gradually. We remind investors that price increases are not likely for EYLEA due to the steep discount offered by off-label Avastin usage. We look for progress on wholly-owned follow-on combinations with EYLEA, such as Ang-2 antibody, in order to re-accelerate long-term growth for Regeneron’s ophthalmology franchise.

Regeneron shares were last seen Wednesday down more than 2% to $452.91. Its consensus analyst target price was closer to $609, and Regeneron has a 52-week trading range of $393.00 to $605.93.

100 Million Americans Are Missing This Crucial Retirement Tool

The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.

Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.

A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.

Click here to learn how to get a quote in just a few minutes.